公开(公告)号：US20230114091A1

公开(公告)日：2023-04-13

申请号：US17783967

申请日：2020-12-14

申请人： Merck Sharp & Dohme LLC

发明人： Michelle Machacek ,  Michael D. Altman ,  Shuhei Kawamura ,  Michael H. Reutershan ,  David L. Sloman ,  Phieng Siliphaivanh ,  Sebastian E. Schneider ,  Charles S. Yeung ,  David J. Witter ,  Craig R. Gibeau

IPC分类号： C07D471/10 ,  C07D519/00

摘要： The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

公开(公告)号：US20230092404A1

公开(公告)日：2023-03-23

申请号：US17787135

申请日：2020-12-14

申请人： MERCK SHARP & DOHME LLC

发明人： Michelle Machacek ,  Michael D. Altman ,  Shuhei Kawamura ,  David L. Sloman ,  David J. Witter ,  Craig R. Gibeau

IPC分类号： C07D519/00

摘要： The present invention provides a compound selected from: and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.